• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DAPSONE Drug Record

  • Summary
  • Interactions
  • Claims
  • DAPSONE chembl:CHEMBL1043 Approved

    Alternate Names:

    DIAPHENYLSULFONE
    DAPSONE
    NSC-6091D
    ACZONE
    DIAMINODIPHENYLSULFONE
    J04BA02
    NSC-6091
    4,4'-SULFONYLBISBENZENAMINE
    4-(4-AMINOPHENYLSULFONYL)BENZENAMINE
    1,1'-SULFONYLBIS[4-AMINOBENZENE]
    P,P-SULPHONYLBISBENZENAMINE
    4,4'-SULFONYLDIANILINE
    4-(4-AMINOPHENYLSULFONYL)ANILINE
    4,4'-DIAMINODIPHENYL SULPHONE
    P,P-SULPHONYLBISBENZAMINE
    BIS(4-AMINOPHENYL)SULFONE
    1,1'-SULFONYLBIS(4-AMINOBENZENE)
    4,4'-SULFONYLBISANILINE
    4,4'-DIAMINODIPHENYLSULFONE
    4-AMINOPHENYL SULFONE
    4,4'-SULFONYLBISBENZENEAMINE
    BIS(P-AMINOPHENYL) SULFONE
    4,4'-DIAMINODIPHENYL SULFONE
    4,4'-DAPSONE
    DDS
    4-(4-AMINO-BENZENESULFONYL)-PHENYLAMINE
    4,4'-SULFONYLDIANILIN
    P,P'-DIAMINODIPHENYL SULFONE
    DADPS
    P-AMINOPHENYL SULFONE
    chembl:CHEMBL1043
    chemidplus:80-08-0
    rxcui:3108
    drugbank:00250
    pubchem.compound:2955

    Drug Info:

    (2 More Sources)

    Publications:

    Dharap et al., 2005, Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide., Proc. Natl. Acad. Sci. U.S.A.
    Cai F et al., 2018, Dapsone-induced drug reaction with eosinophilia and systemic symptoms associated with HLA-B*13:01., Intern Med J
    Chen WT et al., 2018, The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions., J Invest Dermatol
    Tempark T et al., 2017, Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population., Pharmacogenet Genomics
    Zhang FR et al., 2013, HLA-B*13:01 and the dapsone hypersensitivity syndrome., N Engl J Med
    Wang H et al., 2013, Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China., J Invest Dermatol
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Yue Z et al., 2018, Amino Acid Variants of HLA-DRB1 Confer Susceptibility to Dapsone Hypersensitivity Syndrome in Addition to HLA-B*13:01., J Invest Dermatol
    Luzzatto L et al., 2014, G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications., Br J Haematol
    Tungsiripat M et al., 2008, Prevalence and significance of G6PD deficiency in patients of an urban HIV clinic., J Int Assoc Physicians AIDS Care (Chic)
    Alloueche A et al., 2004, Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial., Lancet
    Sulo J et al., 2002, Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial., Lancet
    Youngster I et al., 2010, Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review., Drug Saf
    Luzzatto L, 2010, The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics., Lancet
  • DAPSONE   HLA-B

    Interaction Score: 1.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29512326 29458119 28885988 24152261 23604100


    Sources:
    PharmGKB

  • DAPSONE   GNRH1

    Interaction Score: 1.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16123131


    Sources:
    NCI

  • DAPSONE   HLA-A

    Interaction Score: 0.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29233746


    Sources:
    PharmGKB

  • DAPSONE   CYB5R3

    Interaction Score: 0.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DAPSONE   G6PD

    Interaction Score: 0.7

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24372186 18349424 15183620 12387962 20701405 20599264


    Sources:
    PharmGKB FDA

  • DAPSONE   HLA-DRB1

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29233746


    Sources:
    PharmGKB

  • DAPSONE   CYP2C9

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DAPSONE   CYP3A4

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9187528 22931300


    Sources:
    DTC PharmGKB

  • DAPSONE   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DAPSONE   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • NCI: DDS

    • Version: 14-September-2017

    Alternate Names:
    C415 NCI drug code

    Drug Info:

    Publications:
    Dharap et al., 2005, Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide., Proc. Natl. Acad. Sci. U.S.A.

  • DTC: DAPSONE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1043 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: dapsone

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Yue Z et al., 2018, Amino Acid Variants of HLA-DRB1 Confer Susceptibility to Dapsone Hypersensitivity Syndrome in Addition to HLA-B*13:01., J Invest Dermatol
    Sulo J et al., 2002, Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial., Lancet
    Luzzatto L, 2010, The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics., Lancet

  • TTD: Dapsone

    • Version: 2020.06.01

    Alternate Names:
    D0MA9N TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1043

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Dapsone

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21